Bicycle Therapeutics, a UK-based biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (bicycle) product platform, announced the receipt of a milestone payment in connection with the initiation of a Phase 1 clinical study evaluating THR-149, under its ophthalmology alliance with ThromboGenics NV, a Belgian biopharmaceutical company focused on developing treatments for vitreo-retinal disorders.
ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease. The company’s pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.
THR-149 is a novel plasma kallikrein inhibitor identified and optimized by the Bicycle technology platform. The open-label, multicenter, dose escalation study will evaluate the safety of intravitreally administered THR-149 for the treatment of diabetic macular edema (DME). Initial study results are anticipated in mid-2019.
In addition, Bicycle Therapeutics announced the expansion of the alliance, which aims to identify and optimise additional Bicycles for the treatment of ophthalmic diseases.
Bicycle’s internal focus is in oncology, where the company is developing targeted cytotoxics (Bicycle Toxin Conjugates), targeted innate immune activators and T-cell modulators for cancers of high unmet medical need. Bicycles’ small size and exquisite targeting delivers rapid tumour penetration and retention while clearance rates and routes can be tuned to minimise exposure of healthy tissue and bystander toxicities. Bicycle Therapeutics lead program, BT1718, is rapidly advancing towards the clinic in collaboration with Cancer Research, UK. Bicycle has its headquarters in Cambridge, UK, with many key functions and members of its leadership team located in the biotech hub of Boston (USA).